Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Rating of “Moderate Buy” from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been assigned an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $54.25.

TNDM has been the topic of a number of analyst reports. Robert W. Baird reduced their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada initiated coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price objective on the stock. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective on the stock in a report on Monday, December 2nd. Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Barclays increased their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, November 8th.

Insiders Place Their Bets

In other news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares in the company, valued at $5,855,700. The trade was a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Tandem Diabetes Care by 5.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after purchasing an additional 1,985 shares during the last quarter. LVW Advisors LLC increased its position in shares of Tandem Diabetes Care by 15.1% in the second quarter. LVW Advisors LLC now owns 7,869 shares of the medical device company’s stock worth $317,000 after acquiring an additional 1,034 shares in the last quarter. Diversified Trust Co increased its position in shares of Tandem Diabetes Care by 11.1% in the second quarter. Diversified Trust Co now owns 14,635 shares of the medical device company’s stock worth $590,000 after acquiring an additional 1,462 shares in the last quarter. ORG Partners LLC acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth $31,000. Finally, Tarbox Family Office Inc. acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth $226,000.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock opened at $30.11 on Friday. The firm’s 50 day moving average price is $33.61 and its 200-day moving average price is $40.29. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care has a one year low of $21.85 and a one year high of $53.69. The firm has a market cap of $1.98 billion, a P/E ratio of -15.60 and a beta of 1.32.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same period in the prior year, the business posted ($0.38) EPS. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. As a group, equities research analysts predict that Tandem Diabetes Care will post -1.68 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.